Spruce Biosciences (SPRB) Appoints Kirk Ways to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
June 24, 2021 8:02 AM EDTDr. Ways Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruces Goal to Expand Portfolio of Indications for Tildacerfont
SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and... More



